Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20581854 | 1.00 | KRAS (0.41) | KRASFFAR3CYP1A2MAPTCYP2C9 | |
| SCHEMBL3170 | 0.93 | FFAR3 (0.37) | KRASFFAR3CYP1A2POLB | |
| SCHEMBL8078206 | 0.91 | FFAR3 (0.36) | KRASFFAR3POLB | |
| SCHEMBL27437511 | 0.82 | ALDH1A1 (0.35) | KRASCYP1A2MAPTCYP2C9TSHR | |
| SCHEMBL13144522 | 0.78 | KRAS (0.39) | KRASFFAR3CYP1A2 | |
| SCHEMBL7763991 | 0.78 | GRIN1 (0.33) | POLB | |
| SCHEMBL10046851 | 0.77 | EED (0.42) | MAPTCYP2C9TSHR | |
| SCHEMBL5352623 | 0.77 | EED (0.42) | MAPTCYP2C9TSHR | |
| SCHEMBL29100759 | 0.76 | FFAR3 (0.42) | KRASFFAR3CYP2C9TSHR | |
| SCHEMBL3121522 | 0.76 | POLB (0.37) | MAPTCYP2C9TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571857-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINONE COMPOUNDS | GLAXO GROUP LTD (GB) | 2017-08-23 | — | — | EP | claimed |
| US-20060167281-A1 | 1,2,4- Trioxepanes as precursors for lactones | AKZO NOBEL N.V. (NL) | 2006-07-27 | — | — | US | claimed |
| US-20230400766-A1 | ONIUM SALT, RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230400766-A1 | ONIUM SALT, RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| CN-113429273-A | Synthesis method of metconazole intermediate | 江苏省农用激素工程技术研究中心有限公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-109071567-B | Anti-influenza small molecule compound and preparation method and application thereof | 四川大学 | 2021-03-23 | — | — | CN | disclosed |
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | MARS, INCORPORATED | 2020-08-06 | — | — | US | disclosed |
| US-20200181095-A1 | SELECTIVE MATRIX METALLOPROTEINASE-13 INHIBITORS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2020-06-11 | — | — | US | disclosed |
| CN-106008569-B9 | Borate as arginase inhibitor and composition and application thereof | 马尔斯公司 | 2020-05-22 | — | — | CN | disclosed |
| WO-2000017241-A1 | AUTO-OXIDATION SYSTEMS FOR AIR-ACTIVATABLE POLYMERISABLE COMPOSITIONS | LOCTITE (R & D) LIMITED (IE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0537909-B1 | 3-(Unsubstituted or substituted benzyl)-1-alkyl-2-oxocyclopentane carboxylic acid alkyl ester derivatives, and their preparation and use | KUREHA CHEMICAL IND CO LTD (JP) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995000114-A1 | TETRALINE® FORMATE ESTER AROMA CHEMICALS | UNION CAMP CORPORATION (US) | 1995-01-05 | — | — | WO | disclosed |
| US-5292719-A | Perfumes, colognes, soaps and cosmetics; musk aroma | UNION CAMP CORPORATION (US) | 1994-03-08 | — | — | US | disclosed |
| EP-0419074-B1 | COMPOUND, PREPARATION AND USE | ZENECA LIMITED (GB) | 1993-09-15 | — | — | EP | disclosed |
| EP-0537909-A1 | 3-(Unsubstituted or substituted benzyl)-1-alkyl-2-oxocyclopentane carboxylic acid alkyl ester derivatives, and their preparation and use | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-04-21 | — | — | EP | disclosed |
| US-5082966-A | SULPHINYL COMPOUNDS AND THEIR PREPARATION | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-01-21 | — | — | US | disclosed |
| EP-0419074-A1 | Compound, preparation and use | ZENECA LIMITED (GB) | 1991-03-27 | — | — | EP | disclosed |
| US-4695647-A | RADIOACTIVE MATERIALS | DRUG SCIENCE FOUNDATION (US) | 1987-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | KRAS 1640/4885FFAR3 1519/4885CYP1A2 423/4885 |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | ARG1, ARG2, PRMT1 | KRAS 1640/4885FFAR3 1519/4885CYP1A2 423/4885 |
| US-20060167281-A1 | 1,2,4- Trioxepanes as precursors for lactones | CYP4X1, LSS, RIOX2 | KRAS 4013/4885FFAR3 996/4885CYP1A2 201/4885 |
| US-20200181095-A1 | SELECTIVE MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP17, MMP16 | KRAS 2919/4885FFAR3 4743/4885CYP1A2 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.